Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BioCardia ( (BCDA) ) has provided an update.
On July 16, 2025, BioCardia announced that Henry Ford Health in Detroit, Michigan, has begun enrolling patients with ischemic heart failure in the company’s pivotal Phase 3 CardiAMP HF II trial. This trial is a confirmatory study of autologous bone marrow-derived mononuclear cell therapy, aiming to promote microvascular repair and improve heart function in patients with ischemic heart failure. The trial seeks to confirm the safety and efficacy results observed in previous studies and could potentially enhance treatment options for patients with heart failure.
The most recent analyst rating on (BCDA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
Spark’s Take on BCDA Stock
According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral.
BioCardia faces substantial financial challenges with negative earnings and reliance on external financing. While there are positive developments in clinical trials and corporate events, these are overshadowed by financial instability. Technical indicators provide mixed signals, and valuation remains a concern with negative returns.
To see Spark’s full report on BCDA stock, click here.
More about BioCardia
BioCardia, Inc., based in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary diseases. The company is developing biotherapeutic platforms such as CardiAMP autologous and CardiALLO allogeneic cell therapies, supported by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Average Trading Volume: 135,044
Technical Sentiment Signal: Sell
Current Market Cap: $12.82M
See more data about BCDA stock on TipRanks’ Stock Analysis page.